

Sent By: ONYX PHARMACEUTICALS;

510 222 9758;

Mar-23-04 3:10PM;

Page 4

Atty Docket: ONYX1022-CPA
Serial No. 09/472,691
Response filed March 19, 2004
Page 4 of 7

Remarks

Applicants will address the Examiner's remarks in the order presented by the Examiner in the Office Action mailed January 9, 2004 and subsequent Advisory Action mailed March 10, 2004.

Applicants acknowledge Examiners allowance of Claims 1, 2, 3, 4, 5, 6, 12, 13, and 14

Claim Objections

The Examiner has requested that claims 10 and 15 be placed in proper format. Applicants have changed the status of Claim 10 and Claim 15 in accordance with 37 CFR §1.121. Claim 10 now reads "currently amended" and Claim 15 reads "canceled".

Claim Rejections-35 U.S.C. § 112, Second Paragraph

Claims 7 – 11 remain rejected under 35 U.S.C. § 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which Applicants regard as the invention.

Specifically, the Examiner has stated that claims 7-11 recite "said adenoviral vectors," for which there is no antecedent basis. The Examiner has suggested amending the claims to read "said adenoviral vector," and Applicants have done so.

In light of the amendments discussed above, wherein the word "vectors" has been replaced with "vector," Applicants respectfully request that the rejection be withdrawn and that these claims be allowed.

Sent By: ONYX PHARMACEUTICALS;

510 222 9758;

Mar-23-04 3:11PM;

Page 5


Atty Docket: ONYX1022-CPA
Serial No. 09/472,691
Response filed March 19, 2004
Page 5 of 7

If the Examiner believes that an interview would expedite the prosecution of Applicants' patent application, the Examiner is encouraged to call the undersigned. Applicants also wish to provide the examiner with a clean version (**Appendix A**) of the claims after the entry of this Amendment.

Applicants believe that no fees are due at this time. However, should the Commissioner determine otherwise, the Commissioner is authorized to charge any fees associated with this communication to Deposit Account No. 15-0615 for any matter in connection with this response, including any fee for extension of time, which may be required.

Respectfully submitted,

Date: March 23, 2004

By: 
Gregory Diotta
Reg. No. 32,028

ONYX Pharmaceuticals, Inc.
3031 Research Drive
Richmond, California 94806
Telephone (510) 262-8710
Facsimile (510) 222-9758